常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-5.20/0.81
|
|
企業價值
556.22M
|
| 資產負債 |
|
每股賬面淨值
5.48
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
135.16M
|
|
每股收益
2.62
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2025/11/16 04:39 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others. |

9.93 
